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Abstract
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK, TNFSF12) is a member of the tumor necrosis factor
superfamily. TWEAK activates the Fn14 receptor, and may regulate cell death, survival and proliferation in tumor cells.
However, there is little information on the function and regulation of this system in prostate cancer. Fn14 expression and
TWEAK actions were studied in two human prostate cancer cell lines, the androgen-independent PC-3 cell line and
androgen-sensitive LNCaP cells. Additionally, the expression of Fn14 was analyzed in human biopsies of prostate cancer.
Fn14 expression is increased in histological sections of human prostate adenocarcinoma. Both prostate cancer cell lines
express constitutively Fn14, but, the androgen-independent cell line PC-3 showed higher levels of Fn14 that the LNCaP cells.
Fn14 expression was up-regulated in PC-3 human prostate cancer cells in presence of inflammatory cytokines (TNFa/IFNc)
as well as in presence of bovine fetal serum. TWEAK induced apoptotic cell death in PC-3 cells, but not in LNCaP cells.
Moreover, in PC-3 cells, co-stimulation with TNFa/IFNc/TWEAK induced a higher rate of apoptosis. However, TWEAK or
TWEAK/TNFa/IFNc did not induce apoptosis in presence of bovine fetal serum. TWEAK induced cell death through
activation of the Fn14 receptor. Apoptosis was associated with activation of caspase-3, release of mitochondrial cytochrome
C and an increased Bax/BclxL ratio. TWEAK/Fn14 pathway activation promotes apoptosis in androgen-independent PC-3
cells under certain culture conditions. Further characterization of the therapeutic target potential of TWEAK/Fn14 for human
prostate cancer is warranted.
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Introduction
Prostate cancer is the second leading cause of cancer-related
death in males [1]. Most cases of prostate cancer present as
localized disease and may be cured with surgery and radiation.
However, as is true with most solid malignancies, the development
of metastatic disease is ultimately lethal. Despite active systemic
therapies, the metastatic phenotype will drive in the development
of resistance and disease progression. Moreover, systemic treat-
ments in prostate cancer are limited. Until recently, there were
only three FDA-approved chemotherapeutic agents for use in
castrate-resistant prostate cancer (estramustine, mitoxantrone, and
docetaxel) and two additional agents were approved in 2010
(sipuleucel-T and cabazitaxel [2]. However, there is still a clear
need to develop additional systemic therapies. The growth of
normal prostate epithelial cells is under the tight control of various
growth factors, most notably androgens, castration leads to
apoptosis of this cell population. Androgen-depletion has a similar
effect on prostate cancers. However, following initial regression
tumors often return in an androgen-depletion independent form
that is frequently lethal. Thus, it is of particular interest to search
for agents able to kill androgen-independent prostate cancer cells.
Tumor necrosis factor (TNF) was originally described as a factor
toxic for tumors [3,4]. It was later shown to belong to the TNF
superfamily (TNFSF) of cytokines [5,6]. Many TNFSF cytokines
regulate cell death and proliferation, as well as inflammation and
may have a role in tumor biology, including prostate cancer
biology [7–9]. As an example, recent attention has focused on the
anti-tumor activity of TNF-related apoptosis-inducing ligand
(TRAIL) [10,11]. However, in vivo prostate cancers express
osteoprotegerin, a decoy receptor for both TRAIL and activator of
nuclear factor-kB ligand (RANKL) [12]. TNFSF cytokines
activate a family of receptors (TNFRSF) many of which carry a
death domain (DD) and function as death receptors. Activation of
death receptors in tumor cells by cytotoxic immune cells is the
main mechanism by which the immune system eliminates
malignant cells [13].
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK,
Apo3L, TNFSF12) is one of the most recent members of TNFSF
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to be identified [14,15]. TWEAK was originally described as an
inducer of apoptosis in tumor cells. In addition, TWEAK can
regulate cell proliferation, cell death, cell migration, cell differen-
tiation, tissue regeneration, neoangiogenesis and inflammation
[16–24]. TWEAK activates a single receptor, fibroblast growth
factor-inducible-14 (Fn14, TWEAK receptor, TNFRSF12A,
CD266). TWEAK activation of the Fn14 receptor results in
apoptotic cell death of multiple tumor cell lines [22,25–29].
Indeed, a phase I clinical trial of a humanized anti-TWEAK
receptor monoclonal antibody in subjects with advanced solid
tumors was recently completed [30]. However, TWEAK-Fn14 up-
regulates VEGF expression to foster ovarian cancer cell metastasis
[31] and promotes breast cancer cell invasive capacity [32]. There
is evidence that the different, even opposed, actions of TWEAK
could be determined by the microenvironment. In this regard,
TWEAK induces apoptosis in renal tubular cells in a pro-
inflammatory environment, while, it promotes proliferation in
presence of bovine fetal serum [33,34]. Prostate cancer cells have
been shown to express Fn14 and high expression of Fn14 was
significantly associated with higher prostate-specific antigen
recurrence rate in patients who underwent radical prostatectomy
[35]. Fn14 was highly expressed in androgen-independent prostate
cancer cell lines, DU145 and PC-3, whereas expression was weak
in androgen-sensitive LNCaP cells. A role for Fn14 in migration,
invasion and proliferation was described in PC-3 cells [35].
We now explore the manipulation of the cell culture conditions
as a potential tool to turn the TWEAK/Fn14 system against the
tumor. We report that the inflammatory cytokines and survival
factor from serum modulate the response of PC-3 cells to
TWEAK. In the absence of serum TWEAK/Fn14 pathway
activation promotes apoptosis in androgen-independent PC-3
cells, but not in androgen-sensitive LNCaP cells. A better
understanding of this regulation may turn a potential advantage
of tumor cells into a therapeutic opportunity.
Methods
Cells and Reagents
Two human prostate cancer cell lines were used: the androgen-
independent PC-3 cell line and androgen-sensitive LNCaP cells
(ATCC, Rockville, MD; CRL 1435 and 1740, respectively)
[36,37]. Cells were grown in RPMI 1640 with 10% fetal bovine
serum (FBS), 2 mM glutamine, and antibiotics (100 U/ml of
penicillin and 100 mg/ml of streptomycin), in 5% CO2 at 37uC.
RPMI-1640, penicillin, streptomycin, and trypsin-EDTA were
from BioWhittaker (Waltham, MA) and FBS from Gibco
(Carlsbad, CA). For experiments, cells were serum-depleted for
24 hours, and then treated with different stimuli. As positive
control of Fn14 expression human proximal tubular epithelial
(HK-2) cells (ATCC, CRL 2190) were used [38].
Recombinant human TWEAK (Millipore, Billerica, MA),
unless otherwise specified, was used at 100 ng/mL. ITEM-2
neutralizing anti-Fn14 antibody (eBioscience, San Diego, CA),
neutralizing anti-TWEAK antibody (BioLegend, San Diego, CA)
and neutralizing anti-TNF antibody (BioLegend) were added 1
hour prior to stimuli. Human TNFa (PrePotech, London, UK) at
30 ng/mL, and human interferon-c (IFNc) (PrePotech) at 30 U/
ml, were used in some experiments. All these concentrations are
based on prior dose-response studies performed in our lab [33,34].
Benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone (zVAD-
fmk) (Calbiochem, San Diego, CA, USA) was dissolved in DMSO
and added 1 hour prior to stimuli. Final concentration of DMSO
in culture did not modulate cell death. Bax inhibitor peptide, P5,
was dissolved in water and was added 1 hour prior to stimuli
(Tocris, Bristol, UK) [38].
Cell Surface Fn14 Expression
Cells were plated at a density of 86104 cells in twelve-well
plates. Following stimulation they were detached with 2 mM
EDTA/1%BSA in PBS, washed, and resuspended in PBS/1%
BSA and blocked for 4 min. Then cells were incubated with 1 mg/
ml anti-Fn14 ITEM4 antibody (eBioscience, San Diego, CA) or an
isotype-matched control antibody for 30 min on ice. Cells were
washed twice, blocked for 4 min and incubated with Alexa488-
labeled goat anti-mouse IgG antibody (1/300, Invitrogen,
Carlsbad, CA) for 45 min on ice in the dark. Following two
additional washes with PBS/1%BSA, cells were resuspended in
1% filtered paraformaldehyde in PBS and analyzed by flow
cytometry using BD CellQuest Software (BD Biosciences, San
Jose, CA) [39].
RNA Extraction and Real-Time Polymerase Chain
Reaction
Total RNA was extracted from cells by the TRI Reagent
method (Sigma) and 1 mg of RNA was reverse transcribed with
High Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA). Pre-developed primer and probe assays for Fn14, and
GAPDH (human) were from Applied (Applied Biosystems).
Quantitative PCR was performed by 7500 Real Time PCR
System with the Prism 7000 System SDS Software (Applied
Biosystems) and RNA expression of different genes was corrected
for GAPDH [40].
Western Blot
Cell samples were homogenized in lysis buffer (50 mM
TrisHCl, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2%
Triton X-100, 0.3% NP-40, 0.1 mM PMSF and 1 mg/ml
pepstatin A) then separated by 12% SDS-PAGE under reducing
conditions. After electrophoresis, samples were transferred to
PVDF membranes (Millipore), blocked with 5% skimmed milk in
PBS/0.5% v/v Tween 20 for 1 hour, washed with PBS/Tween,
and incubated with rabbit polyclonal anti-Fn14 (1:1000, Cell
Signaling, Danvers, MA), mouse monoclonal anti-BclxL (1:500,
Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal
anti-Bax (1:500, Santa Cruz Biotechnology), or rabbit polyclonal
anti-cleaved active caspase 3 (1:500, Cell Signaling). Anti-Fn14
was diluted in 5% BSA and the others antibodies were diluted in
5% milk PBS/Tween. Blots were washed with PBS/Tween and
incubated with appropriate horseradish peroxidase-conjugated
secondary antibody (1:2000, Amersham, Aylesbury, UK). After
washing with PBS/Tween blots were developed with the
chemiluminescence method (ECL) (Amersham). Blots were then
probed with mouse monoclonal anti-a-tubulin antibody (1:2000,
Sigma) and levels of expression were corrected for minor
differences in loading [41].
Apoptosis and Cell Death
10,000 cells were seeded in 12-well plates (Costar, Cambridge,
MA) in 10% FCS RPMI overnight. In some cases they were rested
in serum-free medium for 24 hour. Thereafter, stimuli were added
to subconfluent cells. Apoptosis was characterized by morphologic
and functional criteria. Nuclei of formalin-fixed cells were stained
with DAPI (Sigma) to observe the typical morphological changes,
as previously described [33,42]. For assessment of apoptosis by
flow cytometry adherent cells were pooled with spontaneously
detached cells, and incubated in 100 mg/mL propidium iodide
TWEAK and Prostate Cancer
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(PI), 0.05% NP-40, 10 mg/mL RNAse A in PBS at 4uC for .1 h.
This assay permeabilizes the cells, thus PI stains both live and dead
cells. The percentage of apoptotic cells with decreased DNA
staining (hypodiploid cells) was counted by flow cytometry using
BD CellQuest Software (BD Biosciences) [33,34,42].
To quantify cell death, cells were resuspended in 100 ml of PBS
and stained with 100 mg/mL PI just before to flow cytometry. This
assay is based on the known ability of PI to enter in dead cells. The
percentage of dead cells (stained with PI) and live cells (not stained
cells) was counted by flow cytometry using BD FACS Diva
Software (BD Biosciences).
Assessment of Apoptosis by Annexin V-FITC
Briefly, 56105 cells were washed with ice-cold PBS, resus-
pended in 100 ml binding buffer, and, stained with 2.5 ml of FITC-
Annexin V (Myltenyi Biotec, Bergisch Gladbach, Germany). The
cells were incubated for 15 min at 37uC in the dark. Then, 200 ml
of binding buffer containing PI (20 mg/mL) was added just before
flow cytometry. The cells were analyzed using FACS Canto
Figure 1. Fn14 expression in human prostate carcinoma. A) Prostate adenocarcinoma Gleason score 7 (3+4). Original magnification6200.
Fn14 staining is very positive in grade 3 adenocarcinoma (black arrows) and mildly positive in a high-grade PIN focus (white arrow). No or little
staining is observed in normal gland (arrowheads). B) Detail of adenocarcinoma cells from the same biopsy. Original magnification6400. C) Prostate
adenocarcinoma Gleason score 6 (3+3). Mild Fn14 staining in high-grade grade PIN focus (white arrow), while normal tissue is negative (arrowhead).
Original magnification6200. D) Fn14 staining is very positive in grade 3 adenocarcinoma (black arrows), while normal tissue is negative (arrowheads).
Original magnification6200.
doi:10.1371/journal.pone.0047440.g001
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cytometer and FACS Diva Software (BD Biosciences). Early and
late apoptosis was evaluated on PE fluorescence (PE for PI) versus
FITC fluorescence (FITC for Annexin) plots. Cells stained with
only Annexin V were evaluated as being in early apoptosis; cells
stained with both Annexin V and PI were evaluated as being in
late apoptosis stage.
Figure 2. Fn14 expression in human prostate cancer PC-3 and LNCaP cell lines. A) Analysis of Fn14 and TWEAK mRNA expression by
quantitative RT-PCR. Mean (6SEM) of three independent experiments; *p,0.05 vs LNCaP cells. B) Analysis of Fn14 protein expression by western blot
in human prostate cancer cells cultured with or without 10% FBS for 24 hours. Mean (6SEM) of three independent experiments.*p,0.02 vs LnCAP
cells. {p,0.05 vs 0% FBS PC-3 cells. HK2 cells are shown as positive control. C) Analysis of cell surface expression of Fn14 by flow cytometry.
Representative experiment. Cells were stained with an isotype-matched antibody (white area) or anti-Fn14 antibody (black area).
doi:10.1371/journal.pone.0047440.g002
TWEAK and Prostate Cancer
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Immunostaining
Cells plated onto LabtekTM slides were fixed in 4%
paraformaldehyde and permeabilized in 0.2% Triton X-100/
PBS, washed in PBS and incubated with rabbit polyclonal anti-
active caspase 3 (1:100, Cell Signaling) or anti-cytochrome C
(1:500, BDPharmigen) followed by Alexa-488 or Alexa-633
conjugated secondary antibody respectively (1:300, Invitrogen).
Nuclei were counterstained with propidium iodide or DAPI
respectively.
Immunohistochemistry
Fn14 immunohistochemistry was performed in 5 biopsies from
patients diagnosed of prostate adenocarcinoma, aged 65 to 77
years. The Ethics Committee of Fundacion Jimenez Diaz
approved the study, and informed consent was obtained from
each subject. The antigenic epitope retrieval was performed in
3 mm thick sections of paraffin-embedded tissue using a PTlink
device (with a high pH solution, 95uC, 20 min). The tissue slides
were incubated for 30 min at room temperature with the primary
antibody, rabbit polyclonal anti-Fn14 (1:100, Cell Signaling). For
immunohistochemical staining EnvisionFLEX + visualization
system was used, in a DAKO Autostainerplus platform. The
tissue sections were subsequently counterstained with hematoxylin.
Same sections were incubated without the primary antibody as
negative controls.
Statistics
Statistical analysis was performed using SPSS 11.0 statistical
software. Results are expressed as mean 6SEM for protein and
mRNA expression experiments and as mean6 SD for flow
cytometry experiments. Significance at the p,0.05 level was
assessed by Students t test for two groups of data and ANOVA for
three of more groups.
Results
Expression of Fn14 in Prostate Cancer
Prostate adenocarcinoma biopsies displayed a similar pattern of
Fn14 expression (Figure 1). Fn14 expression was negative in
normal prostate epithelium, mildly positive in high-grade prostatic
intraepithelial neoplasia (PIN) foci and very positive in prostate
adenocarcinoma. This suggests that the cell culture observation
that prostate carcinoma cell lines express Fn14 is clinically relevant
and is concordant with prior reports [35].
Constitutive Fn14 and TWEAK Expression in Human
Prostate Cancer Cells
First, we studied the expression of TWEAK and Fn14, the
TWEAK receptor, in two different human prostate cancer cell
lines, PC-3 and LNCaP. PC-3 is an androgen-independent cell
line, whereas LNCaP is an androgen-sensitive cell line. Both cell
lines constitutively expressed Fn14 at the mRNA (Figure 2.A)
and protein levels (Figure 2.B). Although, basal Fn14 expression,
either mRNA levels or protein levels, was significantly higher in
PC-3 cells compared to LNCaP cells. Moreover, basal levels of
TWEAK also were higher in PC-3 cells compared to LNCaP cells,
as assessed by RT-PCR (Figure 2.A).
Fn14 expression was clearly increased by fetal bovine serum
(FBS) in PC3 cells, and, weakly in LNCaP cells (Figure 2.B).
These results are similar to those reported by Huang et al [35],
and, suggest that Fn14 may have a role in prostate cancer because
is highly expressed in the more aggressive malignant cells. Finally,
we demonstrated by flow cytometry that PC-3 cells expressed
Fn14 in cell surface (Figure 2.C).
TWEAK Increased Fn14 and MCP-1 Expression in Prostate
Cancer Cells
TWEAK is a multifunctional cytokine that can induce
inflammatory molecule production in numerous cell types [40].
We stimulated prostate cancer cells with TWEAK and measured
Fn14 and MCP-1 mRNA levels by RT-PCR. We observed that
TWEAK increased Fn14 and MCP-1 expression in both cell lines,
demonstrating that, the two cell types have functional TWEAK
receptor (Figure 3). However, the time course differed between
the two cell lines, being more transient in LNCaP cells that in PC-
3 cells.
Regulation of Fn14 Expression in PC-3 Cells
In various cell types Fn14 expression is dependent on the
microenvironment [33,34,43,44]. FBS, which is rich in growth
and survival factors, increased Fn14 expression in PC-3 cells at the
mRNA, as assessed by RT-PCR (Figure 4.A) and protein levels,
as measured by western blot (Figure 4.B, E).
The inflammatory cytokines TNFa and IFNc also upregulated
Fn14 mRNA (Figure 4.C) and protein (Figure 4.D, E)
expression in PC-3 cells. The time course of Fn14 upregulation
in response to TNFa/IFNc was delayed with respect to
observations in other cell types [33].
Figure 3. PC-3 and LNCaP cells respond to TWEAK treatment.
PC3 and LNCaP cells were stimulated with 100 ng/mL TWEAK for the
indicated points, and Fn14 and MCP-1 mRNA levels were measured by
RT-PCR. Both cell lines respond to TWEAK, but, the PC-3 response is
more sustained compared to LNCaP cells. Mean (6SEM) of three
independent experiments.*p,0.05 vs control.
doi:10.1371/journal.pone.0047440.g003
TWEAK and Prostate Cancer
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Lethal Effect of TWEAK in Human Prostate Cancer Cells
TWEAK can induce apoptosis, survival or even proliferation
in different tumor cell lines and other cells [27,33,34]. We
studied the lethal effect of TWEAK over prostate cancer cell
lines. TWEAK (100 ng/mL) induced apoptosis in PC-3 cultured
in the absence of FBS. The lethal effect was prevented by FBS
(Figure 5.A). In some cases, TWEAK-induced cell death
requires co-incubation with sensitizers, such as the inflammatory
cytokines TNFa and IFNc [19,33]. In this regard, co-incubation
of TWEAK with TNFa/IFNc strongly increased apoptosis in
PC-3 cells (Figure 5.A). Neither TNFa nor IFNc, alone or
together, induced apoptosis in PC-3 cells (data not shown).
However, TWEAK did not induce apoptosis in serum depleted
LNCaP cells, neither alone, nor in combination with TNFa/
IFNc (Figure 5.B). These results are concordant with the effect
of TWEAK observed in renal tubular cells, where, TWEAK
induces proliferation in non-stressed cells, but, induces apoptosis
in the presence of inflammatory cytokines [33,34]. TWEAK-
Figure 4. Fn14 expression in PC-3 cells is dependent on the microenvironment. A, B) PC-3 prostate cancer cells were cultured with 0% or
5% FBS for 3 or 24 hours. Fn14 mRNA expression was measured by quantitative RT-PCR (A) and Fn14 protein expression was studied by Western blot
(B). Mean (6SEM) of four independent experiments. *p,0.03 versus 0% FBS 3h; #p,0.003 vs 0% FBS 24 hours. C, D) Analysis of Fn14 mRNA
expression (C), and Fn14 protein expression (D) in PC-3 cells treated with TNFa (30 ng/mL)/IFNc (30 u/mL) for 3 or 24 hours. Mean (6SEM.) of four
independent experiments. #p,0.03 vs control 24 hours. E) Representative Western blot of Fn14 in PC-3 cells cultured with 0%FBS, 5%FBS or TNFa/
IFNc for 3 and 24 hours.
doi:10.1371/journal.pone.0047440.g004
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Figure 5. TWEAK induces apoptosis in serum depleted androgen-independent PC-3 cells but not in androgen-sensitive LNCaP cells.
Cell death was assessed by flow cytometry of DNA content. Hypodiploid cells were considered apoptotic. A) PC-3 cells, cultured with or without 10%
FBS, were stimulated with TWEAK (100 ng/mL) alone or in presence of TNFa (30 ng/mL)/IFNc (30 U/mL) for 24 hours. Mean (6SD) of four
independent experiments. *p,0.002 vs control; #p,0.001 vs TWEAK alone; {p,0.002 vs 0% FBS with stimuli. B) LNCaP cells, cultured without FBS,
were stimulated with TWEAK alone or in combination with TNFa/IFNc for 24 hours. Mean (6SD) of three independent experiments. C) TWEAK, alone
or in combination with TNFa/IFNc, induces apoptosis in PC-3 cells in a dose-dependent manner. Mean (6SD) of three independent experiments.
*p,0.002 vs control; #p,0.0001 vs control. D) Time-course of TWEAK-induced apoptosis in PC-3 cells, alone or in combination with TNFa/IFNc.
Mean (6SD) of three independent experiments. *p,0.002 vs control; #p,0.0001 vs control.
doi:10.1371/journal.pone.0047440.g005
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induced apoptosis in PC-3 cells is TWEAK dose-dependent
(Figure 5.C) and is observed from 18 hours (Figure 5.D).
Fn14 Mediates the Lethal Effect of TWEAK Over PC-3 Cells
While Fn14 is the only characterized TWEAK receptor, there
is evidence for a second TWEAK receptor, and TWEAK can
bind to CD163 [45,46]. Therefore, we investigated whether
TWEAK induces apoptosis in PC-3 cells through Fn14
activation. Pre-treatment with neutralizing anti-Fn14 (ITEM-2)
or anti-TWEAK antibodies prevented TWEAK- (Figure 6.A)
or TWEAK/TNFa/IFNc-induced apoptosis (Figure 6.B-C).
These results suggest that TWEAK induces apoptosis in PC-3
cells through Fn14 activation. However, TWEAK may induce
apoptosis through recruitment of endogenous TNF/TNF
receptor 1 (TNFR1) [47]. To rule out this mechanism, we
pre-stimulated PC-3 cells with an anti-TNF neutralizing
antibody. Anti-TNF treatment did not prevent TWEAK-
induced apoptosis in PC-3 cells (Figure 6.A).
Characterization of TWEAK-induced Apoptosis in PC-3
Cells
TWEAK-induced apoptosis in PC-3 cells was assessed both by
the presence of hypodiploid cells measured by flow cytometry and
by the typical morphology (nuclear shrinkage, condensation and
fragmentation as well as decreased cell size) (Figure 7.A–B). In
Annexin V/PI assays, TWEAK increased the percentage of
apoptotic cells in PC-3 cells cultured the in absence of serum, and
this was more evident in cells treated with TWEAK/TNFa/IFNc.
However, neither TWEAK nor TWEAK/TNFa/IFNc increased
the number of apoptotic cells in the presence of serum
(Figure 7.C). In addition, TWEAK did not increase Annexin
V/PI positive cells in the LNCaP cell line (data not shown). We
then studied the levels of proteins of the Bcl2 family. TWEAK and
TWEAK/TNFa/IFNc increased proapoptotic Bax levels
(Figure 8.A), downregulated antiapoptotic BclxL levels
(Figure 8.B), and increased the final Bax/BclxL ratio
(Figure 8.C). These results indicate that TWEAK modulates
proteins of the Bcl2 family to favor the apoptosis cell death.
Moreover, a Bax inhibitor peptide (P5) dose-dependently de-
creased TWEAK-induced apoptosis in PC3 cells, further suggest-
ing recruitment of Bax and the mitochondrial pathway
(Figure 8.D). To confirm the involvement of the mitochondrial
apoptosis pathway we performed immunofluorescence of cyto-
chrome C (Cyt C). Unstimulated cells showed mitochondrial Cyt
C staining, whereas, in presence of TWEAK/TNFa/IFNc some
cells showed Cyt C release, indicating that this pathway is
activated (Figure 9).
TWEAK-induced Apoptosis in PC-3 Cells is Caspase
Dependent
Next, we studied the mechanisms of TWEAK-induced apop-
tosis in PC-3 cells. Pretreatment with a pan-caspase inhibitor,
zVAD, prevented TWEAK/TNFa/IFNc-induced apoptosis in
PC-3 cells, indicating that the apoptosis is caspases-dependent
(Figure 10.A). Western blot showed processing of pro-caspase 3
to yield active caspasa-3 in presence of TWEAK at 6 hours. This
effect was stronger and earlier in presence of TWEAK/TNFa/
IFNc (Figure 10.B). In presence of 10%FBS the TWEAK/
TNFa/IFNc combination barely activated caspase 3
(Figure 10.C). Immunofluorescence using an anti-active cas-
pase-3 antibody confirmed caspase-3 activation (Figure 10.D). In
some cells stimulated with TNFSF cytokines, caspases inhibition
prevents apoptotic cell death, but, induces necrotic cell death [33].
In cell death assays staining with PI, zVAD protected from the cell
death induced by TWEAK/TNFa/IFNc at the same level that
anti-TWEAK antibody. This result indicates that caspase inhibi-
tion does not induce necrosis in PC-3 cells stimulated with
TWEAK (Figure 11).
Figure 6. TWEAK or Fn14 antagonism prevents apoptosis
induced by TWEAK or TWEAK/TNFa/IFNc in PC-3 cells. Cell death
was assessed by flow cytometry of DNA content. A) PC-3 cells were pre-
treated with anti-TWEAK neutralizing antibody (10 mg/ml), ITEM2 anti-
Fn14 antibody (10 mg/ml), or anti-TNFa neutralizing antibody (10 mg/
ml), added 1 hour before TWEAK. Cell death was assessed at 24 hours.
Mean (6SD) of three independent experiments. *p,0.02 vs control;
#p,0.0001 vs TWEAK alone. B), C) PC-3 cells were pre-treated with
anti-TWEAK neutralizing antibody (B) or with ITEM2 anti-Fn14 antibody
(C), added 1 hour before TWEAK/TNFa/IFNc. Cell death was assessed at
24 hours. Mean (6SD) of three independent experiments. *p,0.02 vs
control; #p,0.0001 vs TWEAK/TNFa/IFNc alone.
doi:10.1371/journal.pone.0047440.g006
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Figure 7. TWEAK-induced PC-3 cell death has features of apoptosis. A) Flow cytometry of DNA content. Note hypodiploid, apoptotic cells
(|__|) among those treated with TWEAK, or with TWEAK/TNFa/IFNc for 24 hrs. Mean (6SD) of four experiments.*p,0.05 vs control. B) Characteristic
shrunk, pyknotic, fragmented nuclei are present among DAPI-stained, TWEAK or TWEAK/TNFa/IFNc-treated cells (arrows), but are infrequent among
control or TNFa/IFNc-treated cells. Magnification x400, detail x1000. C) PC-3 cells were cultured with or without serum and treated with TWEAK or
TWEAK/TNFa/IFNc for 24 hours. Cells were staining with Annexin V/PI and analyzed by flow cytometry. TWEAK increases both early (AnnexinV+/PI2)
TWEAK and Prostate Cancer
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Discussion
The main finding is that cell culture conditions and, possibly the
in vivo microenvironment can be manipulated to sensitize
androgen-independent prostate cancer cells to TWEAK-induced
apoptosis. Inflammatory cytokines and serum regulate both the
expression of Fn14 in human cancer cell line PC-3, as well as the
cell sensitivity to the lethal effect of TWEAK. Interestingly, the
PC-3 androgen-independent cell line was sensitive to the lethal
effect of TWEAK when cultured in the absence of the survival and
mitogenic factors contained in serum. Moreover, an inflammatory
milieu composed of the combination of TNFa/IFNc increased the
lethal effect of TWEAK over these cells. This offers new potential
therapeutic opportunities for androgen-independent prostate
cancer.
We studied the TWEAK/Fn14 system in androgen-sensitive
LNCaP cells and in androgen-independent PC3 cells. Confirming
previous reports [35] we observed a higher expression of Fn14 in
and late (Annexin V+/PI+) apoptosis under serum deprivation conditions. Graphic shows percentage of early and late apoptosis [(AnnexinV+/
PI2)+(AnnexinV+/PI+)]. Mean (6SD) of three independent experiments. *p,0.008 vs control; #p,0.001 vs 0% FBS with stimuli.
doi:10.1371/journal.pone.0047440.g007
Figure 8. TWEAK modulates Bax and BclxL protein levels in PC-3 cells. A), B) PC-3 cells were stimulated with TWEAK or TWEAK/TNFa/IFNc,
and Bax (A) and (B) BclxL protein levels were analyzed by western blot. Mean (6SEM) of three experiments.*p,0.05 vs control. C) Ratio of Bax/BclxL
protein levels in PC-3 cells. Mean (6SEM) of three independent experiments.*p,0.05 vs control. D) PC-3 cells were treated with Bax inhibitor peptide
P5 at indicated doses one hour before to add TWEAK/TNFa/IFNc. Cell death was measured by flow cytometry of DNA content. Mean (6SD) of three
independent experiments. #p,0.002 vs Control; *p,0.05 vs TWEAK/TNFa/IFNc; **p,0.005 vs TWEAK/TNFa/IFNc.
doi:10.1371/journal.pone.0047440.g008
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PC-3 cells than in LNCaP cells. LNCaP cells expressed non-
inducible, low levels of Fn14. Both LNCaP and PC-3 cells respond
to the pro-inflammatory effect of TWEAK. However, the
apoptotic response of both prostate cancer cell lines to TWEAK
differed. LNCaP cells were resistant to TWEAK-induced apop-
tosis, both in the presence or absence of TNFa/IFNc. More
interesting were the results obtained in androgen-independent PC-
3 cells, since androgen independent prostate cancer poses a more
significant therapeutic challenge. Serum-deprived PC-3 cells were
spontaneously sensitive to TWEAK-induced apoptosis and this
effect was increased in an inflammatory milieu. Huang et al [35]
reported that Fn14 increased proliferation and prevented basal
apoptosis in PC-3 cells. However, these results were obtained in
PC-3 cells cultured in the presence of FBS, and we observed the
lethal effect of TWEAK over PC-3 cells cultured in the absence of
serum. This phenomenon has already been observed for non-
prostate cells. Thus, TWEAK alone induced proliferation, not cell
death, in cultured, non-tumor, non-stressed renal tubular epithelial
cells [34]. Upregulation of the Fn14 receptor by the growth factors
present in serum increased the sensitivity of tubular cells to
TWEAK-induced proliferation [34]. By contrast, upregulation of
Fn14 expression in serum-deprived tubular cells by inflammatory
cytokines (TNFa/IFNc) changed the response to TWEAK from
proliferation to cell death [33,34].
An inflammatory milieu resulted in a sustained increase in the
expression of Fn14 in PC-3 cells. However, similar to observation
in tubular cells [34], the level of Fn14 expression may not be the
single mechanism implicated in TWEAK sensitization, as serum
also increased Fn14 expression but did not sensitize to cell death
by TWEAK in PC-3 cells. A similar pattern of sensitivity to
another TNFSF cytokine has been described: PC-3 were reported
to be highly sensitive to TRAIL-induced apoptosis, and LNCaP to
be resistant [48]. Although not confirmed by all authors [49] this
observation may have a biological basis: androgens positively
regulate the expression of the antiapoptotic FADD-like interleu-
kin-1beta-converting enzyme (FLICE)-like inhibitory protein
(FLIP) [50], which blocks transmission of the lethal signal from
TNFRSF receptors that possess a death domain (DD) [51]. This
information is pertinent despite Fn14 lacking a DD because one of
the potential pathways for TWEAK-induced apoptosis is sensiti-
zation to minor amounts of other TNFSF cytokines present in the
microenvironment [52].
We also characterized the molecular and cellular mechanism of
the cell death induced by TWEAK in PC-3 cells. PC-3 treated
with TWEAK showed characteristics of apoptosis, such as
presence of hypodiploid cells, the typical morphology (nuclear
shrinkage, condensation and fragmentation as well as decreased
cell size) and Annexin V/PI staining. Furthermore, we observed
that TWEAK modulated proteins of Bcl2 family, increasing the
Bax/BclxL ratio, and a Bax inhibitor peptide dose-dependently
prevented cell death. TWEAK-induced apoptosis in PC-3 cells
was caspase-dependent. Different to other cell systems caspase
inhibition did not sensitize PC-3 cells to necrotic death [33].
Natural sources of TWEAK in the prostate may include
leukocytes. Thus, T cells express an array of lethal cytokines, such
as TRAIL and TWEAK that are functional in target cell killing
[53,54]. Furthermore, TWEAK mediates the anti-tumor effect of
tumor-infiltrating macrophages [55]. Since these are inflammatory
cells, this information, together with our observation, suggests that
TWEAK may have a role in natural defenses against prostate
cancer. In addition, TWEAK circulates in serum [56]. However,
circulating TWEAK levels may decrease under diverse patholog-
ical circumstances, including chronic kidney disease, vascular
injury and diabetes [57–59]. Interestingly, diabetes appears to
worsen the outcomes of prostate cancer [60,61]. It would be worth
measuring circulating TWEAK levels in metastatic prostate
Figure 9. TWEAK induces cytochrome C release from the mitochondria in PC-3 cells. PC-3 cells treated with for 24 hours showed
mitochondrial cytochrome C release. Confocal microscopy. Cytochrome C in red and DAPI in blue. (Magnification x400, detail x1000). Pictures
representatives of three experiments.
doi:10.1371/journal.pone.0047440.g009
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Figure 10. TWEAK-induced apoptosis in PC-3 cells is dependent on caspase activation. A) Inhibition of caspases with pan-caspase
inhibitor zVAD (20 mM) prevented apoptosis in PC-3 cells stimulated with TWEAK/TNFa/IFNc for 24 hours. Apoptosis was assessed by flow cytometry
of DNA content. Mean (6SD) of three experiments. *p,0.002 vs control; #p,0.001 vs TWEAK/TNFa/IFNc alone. B) Incubation with TWEAK or
TWEAK/TNFa/IFNc resulted in the appearance of active caspase-3 fragments (arrows, representative Western blot), C) and this is barely observed in
presence of 10% FBS. D) Active caspase 3 immunofluorescence in PC-3 cells treated with TWEAK/TNFa/IFNc. Confocal microscopy. Active caspase 3
in green and propidium iodide in red. (Magnification 320x). Pictures representative of three independent experiments.
doi:10.1371/journal.pone.0047440.g010
TWEAK and Prostate Cancer
PLOS ONE | www.plosone.org 12 October 2012 | Volume 7 | Issue 10 | e47440
carcinoma, since low TWEAK availability might be one of the
factors facilitating tumor expansion once it reaches an androgen-
resistant stage. In addition, CD163, a scavenger TWEAK receptor
expressed by certain macrophages [45] and may compromise
TWEAK availability in the context of an inflamed prostate. In this
regard, a biological therapy approach destined to activate the
Figure 11. Inhibition of caspases did not induce necrotic cell death in PC-3 cells. Cell death was assessed by flow cytometry of PI staining.
PC-3 cells treated with TWEAK/TNFa/IFNc for 24 hours showed high levels of cell death, and this was significantly reduced with anti-TWEAK
neutralizing antibody or with pan-caspase inhibitor zVAD. PI stains late apoptotic and necrotic cells. Mean (6SD) of three independent experiments.
*p,0.005 vs control; #p,0.02 vs TWEAK/TNFa/IFNc alone.
doi:10.1371/journal.pone.0047440.g011
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Fn14 receptor in androgen resistant prostate cancer may
complement natural anti-tumor defenses. The use of an activating
antibody may bypass regulatory or maladaptive mechanisms that
lower TWEAK levels.
The recent availability of Fn14 targeting antibodies may
enhance the spectrum of prostate tumors sensitive to TWEAK/
Fn14 modulating therapies. Two different anti-Fn14 antibodies
have shown anti-tumor activity in cultured cells and experimental
models [26] [62,63]. A phase 1 dose escalation trial of PDL192
humanized anti-TWEAK receptor monoclonal antibody in
subjects with advanced solid tumors was recently completed
[30]. An agonistic anti-Fn14 antibody undergoing clinical trials
appears to have dual mechanisms of action, where binding to the
target activates Fn14 and also recruits the immune system to
mediate antibody-dependent cellular cytotoxicity (ADCC) activity
to help destroy the tumor [26]. Recruitment of ADCC may
sensitize to killing by this antibody even Fn14-expressing,
TWEAK-resistant cells.
In conclusion, TWEAK activation of the Fn14 receptor induced
apoptosis in androgen-independent prostate cancer cells, when
stimulated with inflammatory cytokines and deprived of survival
factors. Since that TWEAK/Fn14 system was previously reported
to promote prostate cancer cell proliferation in the presence of
serum, this information may have therapeutic consequences for
treatment of androgen-independent prostate cancer by designing
maneuvers that sensitize tumor cells to TWEAK-induced apop-
tosis or by the use of agonistic anti-Fn14 antibodies [26].
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